Strengths related to the current research. As far as we know, this study is the first to describe the diagnostic utility of hsa-miR-21-5p/hsa-miR-199a-5p and hsa-miR-155-5p/hsa-miR-199a-5p ratios in combination with AFP for an enhanced early diagnosis of clinical CHCV-G4-related HCC and liver cirrhosis. Here, AFP is linked to hepatocellular carcinoma.